inside tracker
inside tracker

Development

A year in Longevity: progress perspectives

2020's journey to extending healthy human Longevity. The journey to Longevity has many stages, whether it's a clinical pipeline, gaining regulatory approval for a drug,...

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

A year in Longevity: science perspectives

Longevity leaders on the key issues facing our sector. Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s...

VC and drug developer scale-up their incubator model

Collaboration set to establish new ventures for drug discovery and development and advance UCSF discoveries to patients. Autobahn Labs has announced a strategic collaboration with...

Longevity biomarker firm to align CROs, pharma and consumers

Cerascreen expands from consumer biomarker testing into clinical trial recruitment and discovery of Longevity compounds. Combining a wide range of consumer biomarker testing kits with...

NAD boosting to reverse senescence and inflammaging

Senescent cells promote NAD tissue decline during aging through CD38 enzymes which can now become a novel therapeutic target. Nicotinamide adenine dinucleotide (NAD) is a...

Sigilon IPO raises $145m to address chronic diseases

Sigilon boosts its human cell therapeutics pipeline through IPO. Sigilon Therapeutics, Inc, a biotech seeking to develop functional cures for chronic diseases through its Shielded...

Deep Longevity reveals highly-accurate aging clock

Epigenetic aging clock DeepMAge has 3-year error margin and could be the most accurate DNA methylation clock to date. Deep Longevity, the Hong-Kong based Longevity...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley's Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge's funding announcement another biotech start-up...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

Viral vector start-up aims to tackle gene therapy Longevity bottleneck

64x Bio will use proprietary platform to spearhead cell and gene therapy manufacture. Gene therapy can be a fantastic tool for targeting chronic age-related conditions;...

Biotech Elevian announces $15m equity financing

The anti-aging company looks to the clinic with Prime Movers Lab leading the round. Massachusets-based Elevian announced this week that it had closed $15 million equity...

Targeting inflammaging: the hidden “inflammapath” inside us

Keystone Bio seeks funding as it gears up for clinical trials of therapeutic targeting the “keystone pathogen” of chronic inflammaging. Lurking in the mouths of...

AgeX Therapeutics reports Q3 financial results

AgeX commercialises its stem cell lines with continued support from stakeholder Juvenescence. Biotech AgeX Therapeutics reported financial and operating results for the third quarter ended...

Let’s initiate trials of potential geroprotective therapies

Dr Lynne Cox explains the importance of geroprotectors – especially during COVID-19. This month The Lancet launches its own journal on Longevity, publishing clinically-focused Longevity and...

AgelessRx and funding an IRB-approved rapamycin trial

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding. AgelessRx is a platform that sells drugs and supplements including...

Oxidants can slow cell aging

Swedish study shows hydrogen peroxide can slow down the cell aging of yeast cells. Known to most as a bleaching agent or antiseptic, hydrogen peroxide...

Biogen Alzheimer’s drug closer to FDA approval

This Longevity category product approval will bode well for our sector and will make institutional investors take note. Biogen's aducanumab, the first drug to actually...
inside tracker
lumen

Latest articles